![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1423530449/image_1423530449.jpg?io=getty-c-w1536)
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Klaus Vedfelt Investment Overview Vertex Pharmaceuticals (NASDAQ:VRTX), the Boston based Pharma giant with an almost monopolistic share of the Cystic Fibrosis treatment market, announced its Q2 2024 earnings at the beginning of August. Product revenues …